Rimcazole (BW234U) in the maintenance treatment of outpatients with schizophrenia
- 1 January 1989
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 16 (1), 79-83
- https://doi.org/10.1002/ddr.430160109
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Open label evaluation of the novel antipsychotic compound BW234U in chronic schizophrenicsDrug Development Research, 1985
- BW234: A nondopamine receptor-blocking antipsychotic drug without extrapyramidal side effects?Drug Development Research, 1984
- An early Phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patientsPsychopharmacology, 1984
- Psychotropic actions of BW 234U in the treatment of inpatient schizophrenics: A dose-range studyDrug Development Research, 1983
- BW234U,(cis-9-[3–(3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride): a novel antipsychotic agentJournal of Pharmacy and Pharmacology, 1982
- Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic DrugsScience, 1976
- Apomorphine-induced aggression in the ratBrain Research, 1971